Brief: Knight Therapeutics Inc. Announces Approval Of Lenvima® In Colombia
04/01/2022 13:25
Jan 4 (Reuters) - Knight Therapeutics Inc GUD.TO :
* KNIGHT THERAPEUTICS INC. ANNOUNCES APPROVAL OF LENVIMA® IN
COLOMBIA
Source text for Eikon: ID:nGNX61nXmh
Further company coverage: GUD.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Knight Therapeutics
See all newsBrief: Knight Therapeutics Announces Regulatory Approval Of Niktimvo In Brazil
Brief: Knight Therapeutics - Launches Tavalisse In Brazil For Chronic Immune Thrombocytopenia
Brief: Knight Therapeutics Enters Into Exclusive Distribution Agreement With Kyowa Kirin International For Poteligeo® (Mogamulizumab)
Brief: Knight Therapeutics Announces Regulatory Approval Of Tavalisse® In Colombia
Brief: Knight Therapeutics Announces Supplemental Regulatory Submission For Minjuvi In Brazil